Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ULD IL-2 for GVHD Prophylaxis in Haplo-SCT
NCT02226861Phase 1Completed
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Aug 2014
- Primary completion
- May 2018
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of aldesleukin in graft-versus-host disease (GVHD), sponsored by National Heart, Lung, and Blood Institute. Primary endpoint: Safety of ULD IL-2 as GVHD prophylaxis at 4 months. Started Aug 2014; status: completed.
02
Drugs
aldesleukin
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT02226861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02226861.